Lode Dewulf, chief patient affairs officer at UCB, tells Paul Tunnah how patient-centricity is evolving, and describes how pharma still needs to adapt.
Novartis has struck another deal to build its position in radiopharmaceuticals, agreeing to pay $1 billion upfront for radioligand therapy (RLT) developer Mariana Oncology
It’s 2024, and in most clinical trials, data is still being moved from the EHR to the EDC manually – with employees reading data from one screen and typing it onto another.